SureTrader SureTrader
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 12/7/2016 2:28:55 AM - Followers: 1311 - Board type: Free - Posts Today: 1

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Calendars and Compilations
Webcasts
Recent Biotech Buyouts
Buyouts of Biotech Partners
FoB Collaborations

Common Biotech-Newbie Mistakes
Biotech Holdings of Selected Institutional Investors
US Patent Expirations for Big-Selling Biologics
Biotech and Miscellaneous Acronyms

Top Twitter Feeds for Biotech Info
iHub's Greatest Hits (thru 5/09)

PostSubject
#206685  Sticky Note BLUE offering $200M xavierprivas 12/06/16 05:06:14 PM
#206679  Sticky Note >>(ALK+) advanced non-small cell lung cancer (NSCLC) treated biomaven0 12/06/16 01:57:29 PM
#206666  Sticky Note Update on SAGE’s phase-3 program in PPD: DewDiligence 12/06/16 09:01:11 AM
#206663  Sticky Note Ariad @ASH released ponatinib updates just now ~Final report puravida 12/06/16 07:50:21 AM
#206662  Sticky Note One of CLLS next targets. From a n4807g 12/06/16 07:19:57 AM
#206651  Sticky Note Re: ABBV’s CP on indication extrapolation for interchangeable FoBs DewDiligence 12/05/16 04:33:08 PM
#206700   bluebird bio (NASDAQ:BLUE) prices a 3.3M share offering lgonber 12/07/16 02:28:55 AM
#206699   >>10b5-1 selling is rules-based biomaven0 12/06/16 10:19:10 PM
#206698   PRTO re B.AVF vs R .AVF Whalatane 12/06/16 08:41:07 PM
#206697   I always thought 105b [plans], once set up, DewDiligence 12/06/16 08:24:10 PM
#206696   I always thought 105b sales ,once set up, linhdtu 12/06/16 08:12:36 PM
#206695   Just prior to going public they spun off jbog 12/06/16 07:32:22 PM
#206694   PTHN—...but earnings were nowhere [near] what I expected. DewDiligence 12/06/16 07:19:38 PM
#206693   Dew, Do you have an updated opinion on PTHN? jbog 12/06/16 07:14:44 PM
#206692   Gazyva—Same comment, different venue: DewDiligence 12/06/16 07:14:24 PM
#206691   BPMC selling $143.8M* of stock on unspecified terms: DewDiligence 12/06/16 07:10:34 PM
#206690   BLUE is actually selling $230M including the underwriter’s DewDiligence 12/06/16 07:08:32 PM
#206689   Hans (JUNO's CEO] claims the sales were pursuant DewDiligence 12/06/16 06:52:42 PM
#206688   PRTO: Re: treatment of RCF vs BCF poorgradstudent 12/06/16 06:45:50 PM
#206687   Hans claims the sales were pursuant to a puravida 12/06/16 05:41:23 PM
#206686   DNA Repair Defects Emerge as a New Category Titan V 12/06/16 05:34:56 PM
#206685   BLUE offering $200M xavierprivas 12/06/16 05:06:14 PM
#206684   Iwfal ...re PRTO and the following Whalatane 12/06/16 04:11:34 PM
#206683   Biotech Investment Bank Research Reports To Beg, Borrow Titan V 12/06/16 03:35:34 PM
#206682   JUNO removed the Q&A portion of its ASH bladerunner1717 12/06/16 03:25:30 PM
#206681   What do you expect with former CEO of xavierprivas 12/06/16 02:21:44 PM
#206680   Damage control lol. I believe it was bradloncar linhdtu 12/06/16 02:03:35 PM
#206679   >>(ALK+) advanced non-small cell lung cancer (NSCLC) treated biomaven0 12/06/16 01:57:29 PM
#206678   MIT is just a trade school ;^) OakesCS 12/06/16 01:14:00 PM
#206677   Factoid—$1B of funding for 21st Century Cures act DewDiligence 12/06/16 12:50:37 PM
#206676   JUNO removed the Q&A portion of its ASH DewDiligence 12/06/16 12:21:01 PM
#206675   How Donald Trump's Corporate Tax Holiday Could Spur Titan V 12/06/16 12:01:35 PM
#206674   This gun sprays stem cells on burn victims Titan V 12/06/16 11:46:27 AM
#206673   "The Patents That Kicked Off the DNA-Editing Gold biotech_researcher 12/06/16 10:53:03 AM
#206672   EPVantage comments on Imbruvica’s would-be competitors: DewDiligence 12/06/16 10:25:37 AM
#206671   The Patents That Kicked Off the DNA-Editing Gold Rush ciciagt 12/06/16 09:47:11 AM
#206670   LXRX -10%/PM on phase-2 Sotagliflozin data in T1D: DewDiligence 12/06/16 09:12:28 AM
#206669   STML SL-401 continues to look promising. n4807g 12/06/16 09:08:16 AM
#206668   GRPOF ...must have biotech http://www.marketwatch.com/story/aphria-makes-100000 MADDSTACKER 12/06/16 09:07:29 AM
#206667   HTBX +21%/PM on combo data with Opdivo: DewDiligence 12/06/16 09:04:36 AM
#206666   Update on SAGE’s phase-3 program in PPD: DewDiligence 12/06/16 09:01:11 AM
#206665   NVS presents Zykadia phase-3 data in first-line ALK+/NSCLC: DewDiligence 12/06/16 08:50:13 AM
#206664   "Ariad @ASH released ponatinib updates just now " Compelling biotech_researcher 12/06/16 07:58:13 AM
#206663   Ariad @ASH released ponatinib updates just now ~Final report puravida 12/06/16 07:50:21 AM
#206662   One of CLLS next targets. From a n4807g 12/06/16 07:19:57 AM
#206661   Forgot board favorite TRIL ASH Webcast link ghmm 12/05/16 09:56:44 PM
#206660   AGIO -12%—shareholder lawsuits filed—on phase-2 data in pyruvate-kinase DewDiligence 12/05/16 08:22:48 PM
#206659   That write-up would more aptly be titled, "Ten DewDiligence 12/05/16 07:23:55 PM
#206658   Another weak Reuters story, IMO. Saying that Bosulif DewDiligence 12/05/16 07:21:35 PM
#206657   Reuters' saying that Gazyva/Treanda vs Rituxan/Treanda raised 3-year DewDiligence 12/05/16 07:18:55 PM
#206656   Pfizer blood cancer drug tops standard therapy for Titan V 12/05/16 06:27:53 PM
#206655   10 Major Pharma and FDA Catalysts Coming in December http://247wallst.com/health Titan V 12/05/16 06:25:02 PM
#206654   Study raises questions over benefit of Roche's Gazyva Titan V 12/05/16 06:15:41 PM
#206653   XXII - Dr. Rushton indicated: We aim to kei 12/05/16 05:22:41 PM
#206652   TXMD +21%/AH on nominal phase-3 success: DewDiligence 12/05/16 05:03:06 PM
#206651   Re: ABBV’s CP on indication extrapolation for interchangeable FoBs DewDiligence 12/05/16 04:33:08 PM
PostSubject